US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased risk of suicidal thoughts or behaviour ...
Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli ...
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...
Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other approved incretin therapies.
The warnings, part of their original approval, were based on reports of such events observed with a variety of older ...
Investor's Business Daily on MSN
Nvidia eyes first breakout of 2026. These clues — and an innovative deal with Eli Lilly — bode well.
Nvidia eyes first breakout of 2026. These clues — and an innovative deal with Eli Lilly — bode well.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback